Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 23584478
Shin S, et al. (2014) Glycogen synthase kinase-3β positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1. Oncogene 33, 1690-9 23584478
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T37-p - 4E-BP1 (human)
Modsite: PPGDysttPGGtLFs SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T37‑p, 4E‑BP1 (mouse): T36‑p, 4E‑BP1 (rat): T36‑p, 4E‑BP1 (fruit fly): T37‑p, 4E‑BP1 (cow): T37‑p
Characterization
Methods used to characterize site in vivo mass spectrometry, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, breast cancer, triple negative
Relevant cell lines - cell types - tissues:  HCC1806 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GSK3B (human) modification site within consensus motif, siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AR-A014418 decrease
1-azakenpaullone decrease
rapamycin no change compared to control
GSK3A (human) no change compared to control shGSK3A no change
Downstream Regulation
Effect of modification (function):  phosphorylation
Effect of modification (process):  cell growth, induced
Comments:  T41 and T50 act as priming sites for T37/46

T41-p - 4E-BP1 (human)
Modsite: ysttPGGtLFsttPG SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T41‑p, 4E‑BP1 (mouse): T40‑p, 4E‑BP1 (rat): T40‑p, 4E‑BP1 (fruit fly): T41‑p, 4E‑BP1 (cow): T41‑p
Characterization
Methods used to characterize site in vivo mass spectrometry, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, breast cancer, triple negative
Relevant cell lines - cell types - tissues:  HCC1806 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Downstream Regulation
Effect of modification (function):  phosphorylation
Effect of modification (process):  cell growth, induced
Comments:  T41 and T50 act as priming sites for T37/46

T46-p - 4E-BP1 (human)
Modsite: GGtLFsttPGGtRII SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T46‑p, 4E‑BP1 (mouse): T45‑p, 4E‑BP1 (rat): T45‑p, 4E‑BP1 (fruit fly): T46‑p, 4E‑BP1 (cow): T46‑p
Characterization
Methods used to characterize site in vivo mass spectrometry, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, breast cancer, triple negative
Relevant cell lines - cell types - tissues:  HCC1806 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GSK3B (human) modification site within consensus motif, siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AR-A014418 decrease
1-azakenpaullone decrease
rapamycin no change compared to control
GSK3A (human) no change compared to control shGSK3A no change
Downstream Regulation
Effect of modification (function):  phosphorylation
Effect of modification (process):  cell growth, induced
Comments:  T41 and T50 act as priming sites for T37/46

T50-p - 4E-BP1 (human)
Modsite: FsttPGGtRIIyDRk SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T50‑p, 4E‑BP1 (mouse): T49‑p, 4E‑BP1 (rat): T49‑p, 4E‑BP1 (fruit fly): T50‑p, 4E‑BP1 (cow): T50‑p
Characterization
Methods used to characterize site in vivo mass spectrometry, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, breast cancer, triple negative
Relevant cell lines - cell types - tissues:  HCC1806 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Downstream Regulation
Effect of modification (function):  phosphorylation
Effect of modification (process):  cell growth, induced
Comments:  T41 and T50 act as priming sites for T37/46

S65-p - 4E-BP1 (human)
Modsite: FLMECrNsPVtktPP SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): S65‑p, 4E‑BP1 (mouse): S64‑p, 4E‑BP1 (rat): S64‑p, 4E‑BP1 (fruit fly): S65‑p, 4E‑BP1 (cow): S65‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, breast cancer, triple negative
Relevant cell lines - cell types - tissues:  HCC1806 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AR-A014418 decrease
1-azakenpaullone decrease
rapamycin no change compared to control
GSK3A (human) no change compared to control shGSK3A no change

T70-p - 4E-BP1 (human)
Modsite: rNsPVtktPPRDLPt SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T70‑p, 4E‑BP1 (mouse): T69‑p, 4E‑BP1 (rat): T69‑p, 4E‑BP1 (fruit fly): T70‑p, 4E‑BP1 (cow): T70‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, breast cancer, triple negative
Relevant cell lines - cell types - tissues:  HCC1806 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AR-A014418 decrease
1-azakenpaullone decrease
rapamycin no change compared to control
GSK3A (human) no change compared to control shGSK3A no change

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, breast cancer, triple negative
Relevant cell lines - cell types - tissues:  HCC1806 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AR-A014418 no change compared to control
1-azakenpaullone no change compared to control
rapamycin no change compared to control
GSK3B (human) no change compared to control shGSK3B no effect

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, breast cancer, triple negative
Relevant cell lines - cell types - tissues:  HCC1806 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AR-A014418 no change compared to control
1-azakenpaullone no change compared to control
rapamycin no change compared to control
GSK3B (human) no change compared to control shGSK3B no effect

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, breast cancer, triple negative
Relevant cell lines - cell types - tissues:  HCC1806 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AR-A014418 no change compared to control
1-azakenpaullone no change compared to control
rapamycin no change compared to control
GSK3B (human) no change compared to control shGSK3B no effect

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, breast cancer, triple negative
Relevant cell lines - cell types - tissues:  HCC1806 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AR-A014418 no change compared to control
1-azakenpaullone no change compared to control
rapamycin no change compared to control
GSK3B (human) no change compared to control shGSK3B no effect

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, breast cancer, triple negative
Relevant cell lines - cell types - tissues:  HCC1806 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AR-A014418 no change compared to control
1-azakenpaullone no change compared to control
rapamycin no change compared to control
GSK3B (human) no change compared to control shGSK3B no effect

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, breast cancer, triple negative
Relevant cell lines - cell types - tissues:  HCC1806 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GSK3B (human) increase GSK3B shRNA inhibits
AR-A014418 decrease
1-azakenpaullone decrease
rapamycin decrease

S235-p - S6 (human)
Modsite: IAKRRRLssLRAsts SwissProt Entrez-Gene
Orthologous residues
S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p, S6 (fruit fly): A234‑p, S6 (cow): S235‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, breast cancer, triple negative
Relevant cell lines - cell types - tissues:  HCC1806 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GSK3B (human) increase GSK3B shRNA inhibits
AR-A014418 decrease
1-azakenpaullone decrease
rapamycin decrease

S236-p - S6 (human)
Modsite: AKRRRLssLRAstsK SwissProt Entrez-Gene
Orthologous residues
S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p, S6 (fruit fly): S235‑p, S6 (cow): S236‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, breast cancer, triple negative
Relevant cell lines - cell types - tissues:  HCC1806 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
GSK3B (human) increase GSK3B shRNA inhibits
AR-A014418 decrease
1-azakenpaullone decrease
rapamycin decrease